- Home
- LCTX vs RDCM Comparison
LCTX vs RDCM Comparison
Compare LCTX & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- RDCM
- Stock Information
- Founded
- LCTX 1990
- RDCM 1985
- Country
- LCTX United States
- RDCM Israel
- Employees
- LCTX N/A
- RDCM N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- RDCM Computer peripheral equipment
- Sector
- LCTX Health Care
- RDCM Technology
- Exchange
- LCTX Nasdaq
- RDCM Nasdaq
- Market Cap
- LCTX 166.3M
- RDCM 157.9M
- IPO Year
- LCTX N/A
- RDCM 1997
- Fundamental
- Price
- LCTX $0.60
- RDCM $11.71
- Analyst Decision
- LCTX Strong Buy
- RDCM Strong Buy
- Analyst Count
- LCTX 4
- RDCM 1
- Target Price
- LCTX $4.75
- RDCM $14.00
- AVG Volume (30 Days)
- LCTX 909.4K
- RDCM 74.2K
- Earning Date
- LCTX 11-14-2024
- RDCM 11-13-2024
- Dividend Yield
- LCTX N/A
- RDCM N/A
- EPS Growth
- LCTX N/A
- RDCM 660.55
- EPS
- LCTX N/A
- RDCM 0.46
- Revenue
- LCTX $8,719,000.00
- RDCM $58,755,000.00
- Revenue This Year
- LCTX N/A
- RDCM $17.18
- Revenue Next Year
- LCTX $123.52
- RDCM $11.32
- P/E Ratio
- LCTX N/A
- RDCM $24.22
- Revenue Growth
- LCTX N/A
- RDCM 17.80
- 52 Week Low
- LCTX $0.56
- RDCM $7.70
- 52 Week High
- LCTX $1.61
- RDCM $12.44
- Technical
- Relative Strength Index (RSI)
- LCTX 26.43
- RDCM 59.92
- Support Level
- LCTX $0.80
- RDCM $11.16
- Resistance Level
- LCTX $0.97
- RDCM $11.91
- Average True Range (ATR)
- LCTX 0.07
- RDCM 0.54
- MACD
- LCTX -0.03
- RDCM 0.08
- Stochastic Oscillator
- LCTX 9.45
- RDCM 67.26
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.